More than 2,000 patient groups responded to PatientView’s annual “Pharmaceutical Industry Corporate Reputation” survey.
PatientView today publishes the results of the latest “Pharmaceutical Industry Corporate Reputation” survey (now in its 12th edition). Between November 2022 and February 2023, the survey collected the opinion of 2,207 patient groups from around the world on the performance of the pharmaceutical industry during 2022.
Patient groups responding to the 2022 “Pharmaceutical Industry Corporate Reputation” survey are in a unique position to weigh in on the industry and individual pharmaceutical companies, as they are knowledgeable about patient experiences as well as networking with all other stakeholders in the healthcare system.
Summary of Results
across the industry
Concern about the Covid-19 virus decreased worldwide in 2022, but the increased positivity towards the pharmaceutical industry, encouraged in 2020 and 2021 by the pandemic, remained unchanged in 2022. Patient groups around the world continued to considering the pharmaceutical industry as the highest valued among healthcare stakeholders during 2022. The pharmaceutical industry also continued to improve its results (and has been doing so since 2018) in the performance of activities important to patients, in particular, the relationships of the pharmaceutical industry with patient groups.
Despite these achievements, only 32% of patient groups surveyed in 2022 rated the pharmacist as “Excellent” or “Good” at improving patient access to medicines [una nueva medida introducida en la encuesta de “Reputación corporativa” para 2022]. With pandemic-related issues no longer at the fore in most countries by 2022, longer-term health concerns – in particular, the delays patients face in receiving treatment – have once again come to the fore. the first place. Globally, up to 52% of patient groups surveyed considered pharma’s improvement in patient access to medicines to be “fair or poor”. The problem of access was felt particularly strongly in Africa (and surveyed African patient groups considered unfair prices to be just one of many reasons).
“Pharmaceutical companies should sit down to negotiate costs together with MinSal, social works and patient organizations.” National Group of Patients with Rare Diseases, Argentina.
“Have cheaper drug programs for those who have less, than those that are about to expire could be available to patients who do not have enough resources.” National Group of Patients with Renal Disease, Mexico.
“Lately, rare rheumatology patients have joined demonstrations and marches to make the government and the pharmaceutical industry aware of their existence. Look at us and welcome him.“ Regional Group of Patients with Scleroderma, Brazil.
private companies
The 42 companies evaluated in this survey were selected based on the following criteria: revenue volume; or at the request of companies or patient groups:
• AbbVie • Amgen • Astellas Pharma • AstraZeneca • Bayer • Biogen • Biomarin • Boehringer Ingelheim • Bristol Myers Squibb • Chiesi Farmaceutici • CSL Behring • Daiichi Sankyo • Eisai • Eli Lilly • Ferring • Gilead Sciences • Grifols • Grünenthal • GSK • Horizon Therapeutics • Ipsen • Janssen • LEO Pharma • Lundbeck • Menarini • Merck & Co • Merck KgaA • Novartis • Novo Nordisk • Octapharma • Otsuka • Pfizer • Pierre Fabre • PTC Therapeutics • Roche • Sanofi • Sarepta Therapeutics • Servier • Takeda • UCB • Vertex • ViiV Healthcare
88% of the 2,207 patient groups surveyed in 2022 said they work directly with pharmacists, suggesting that both patient groups and pharmacists accept pharmacist-patient group relationships as a normal and acceptable trend in care sanitary.
World top-three rankings
Of the 42 companies:
➔ According to the evaluation of groups of surveyed patients familiar with the company
1st: Roche
2nd: ViiV Healthcare
3rd: Horizon Therapeutics
➔ According to the evaluation of the groups of surveyed patients who work with the company
1st: ViiV Healthcare
2nd: Horizon Therapeutics
3rd: Roche
Of the 15 “Big Pharma” companies:
➔ According to the evaluation of groups of surveyed patients familiar with the company
1st: Roche
2nd: Pfizer3rd: Gilead Sciences
➔ According to the evaluation of the groups of surveyed patients who work with the company
1st: Roche
2nd: Gilead Sciences
3rd: Pfizer
The companies that rise the most at the top of the ranking (of the 42 companies), 2022 vs. 2021, according to the assessment of the surveyed patient groups familiar with the company.
PROFILE OF RESPONDENTS
2,207 patient groups responded to the “Corporate Reputation of Pharma” survey in its 12th edition, a record number.
Responding patient groups have reached approximately 32 million patients through 2022.
Finally, PatientView would like to thank the 2,207 patient groups and health advocates who have dedicated their time to respond to the 2022 “Pharmaceutical Industry Corporate Reputation” survey (published in 2023).
The surveyed patient groups believe that exchanging views and experiences on whether the pharmaceutical industry (and individual pharmaceutical companies) meet their needs and expectations will help the industry gain valuable feedback for improvement.
As many of the 42 pharmaceutical companies included in the 2022 “Pharmaceutical Industry Corporate Reputation” survey are strategizing around patients, the survey results may influence company models and approaches, enabling greater adaptation to the needs and perspectives of patients.
For more information about this global report, please use the contact details in the header of the press release.